Abstract
Main neuropathological hallmarks of Alzheimers disease (AD) and other neurodegenerative disorders are the deposition of neurofibrillary tangles consisting of abnormally phosphorylated protein tau and of senile plaques largely containing insoluble ß-amyloid peptides (Aß), containing up to 43 amino acid residues derived from the ß-amyloid precursor protein. Such Aß-sheets become visible by using suitable histochemical methods. Molecular simulation showed that the central, α-helical, lipophilic, antigenic folding domain of the Aßpeptide loop is a promising molecular target of ß-sheet breakers that thus prevent the polymerization of Aß into aggregates. It seems that di- and tetramers of Aß-peptides have a ß-barrel- like structure. In the present review, an optimized neural network analysis was applied to recognize possible structureactivity relationships of peptidomimetic ß-sheet breakers. The anti-aggregatory potency of ß-sheet breakers largely depends upon their total, electrostatic, and hydration energy as derived from their geometry-optimized conformations using the hybrid Gasteiger-molecular mechanics approach. Moreover, we also summarize peptide misfolding in several disorders with distinct clinical symptoms, including prion diseases and a broad variety of systemic amyloidoses, as the common pathogenic step driving these disorders. In particular, conversion of nontoxic α-helix / random-coils to ß-sheet conformation was recognized as being critical in producing highly pathogenic peptide assemblies. Whereas conventional pharmacotherapy of AD is mainly focused on restoring cholinergic activity and diminishing inflammatory responses as a consequence of amyloid accumulation, we here survey potential approaches aimed at preventing or reserving the transition of neurotoxic peptide species from α- helical / random coil to ß-sheet conformation and thus abrogating their effects in a broad variety of disorders.
Keywords: Pathological Peptide, Alzheimers Disease, Gasteiger-molecular
Current Medicinal Chemistry
Title: Pathological Peptide Folding in Alzheimers Disease and Other Conformational Disorders
Volume: 9 Issue: 19
Author(s): Peter P. Mager, Botond Penke, Regina Walter, Tibor Harkany and Wolfgang Hartig
Affiliation:
Keywords: Pathological Peptide, Alzheimers Disease, Gasteiger-molecular
Abstract: Main neuropathological hallmarks of Alzheimers disease (AD) and other neurodegenerative disorders are the deposition of neurofibrillary tangles consisting of abnormally phosphorylated protein tau and of senile plaques largely containing insoluble ß-amyloid peptides (Aß), containing up to 43 amino acid residues derived from the ß-amyloid precursor protein. Such Aß-sheets become visible by using suitable histochemical methods. Molecular simulation showed that the central, α-helical, lipophilic, antigenic folding domain of the Aßpeptide loop is a promising molecular target of ß-sheet breakers that thus prevent the polymerization of Aß into aggregates. It seems that di- and tetramers of Aß-peptides have a ß-barrel- like structure. In the present review, an optimized neural network analysis was applied to recognize possible structureactivity relationships of peptidomimetic ß-sheet breakers. The anti-aggregatory potency of ß-sheet breakers largely depends upon their total, electrostatic, and hydration energy as derived from their geometry-optimized conformations using the hybrid Gasteiger-molecular mechanics approach. Moreover, we also summarize peptide misfolding in several disorders with distinct clinical symptoms, including prion diseases and a broad variety of systemic amyloidoses, as the common pathogenic step driving these disorders. In particular, conversion of nontoxic α-helix / random-coils to ß-sheet conformation was recognized as being critical in producing highly pathogenic peptide assemblies. Whereas conventional pharmacotherapy of AD is mainly focused on restoring cholinergic activity and diminishing inflammatory responses as a consequence of amyloid accumulation, we here survey potential approaches aimed at preventing or reserving the transition of neurotoxic peptide species from α- helical / random coil to ß-sheet conformation and thus abrogating their effects in a broad variety of disorders.
Export Options
About this article
Cite this article as:
Mager P. Peter, Penke Botond, Walter Regina, Harkany Tibor and Hartig Wolfgang, Pathological Peptide Folding in Alzheimers Disease and Other Conformational Disorders, Current Medicinal Chemistry 2002; 9 (19) . https://dx.doi.org/10.2174/0929867023369169
DOI https://dx.doi.org/10.2174/0929867023369169 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets PCR/SSCP Detects Reliably and Efficiently DNA Sequence Variations in Large Scale Screening Projects
Combinatorial Chemistry & High Throughput Screening Neurobiological and Psychosocial Processes Associated with Depressive and Substance-Related Disorders in Adolescents
Current Drug Abuse Reviews From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?
Current Medical Imaging Cholesterol Homeostasis Failure in the Brain: Implications for Synaptic Dysfunction and Cognitive Decline
Current Medicinal Chemistry Elicitation of Dopaminergic Features of Parkinson’s Disease in C. elegans by Monocrotophos, an Organophosphorous Insecticide
CNS & Neurological Disorders - Drug Targets Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Amyloid Deposition and Inflammation in APPswe/PS1dE9 Mouse Model of Alzheimers Disease
Current Alzheimer Research Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Essential Oils and Pure Volatile Compounds as Potential Drugs in Alzheimer’s Disease Therapy: An Updated Review of the Literature
Current Pharmaceutical Design Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD
Current Alzheimer Research Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism